Handelsbanken Fonder AB Purchases 10,400 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Handelsbanken Fonder AB grew its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 9.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 123,200 shares of the company’s stock after buying an additional 10,400 shares during the period. Handelsbanken Fonder AB’s holdings in Krystal Biotech were worth $15,284,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of KRYS. Vanguard Group Inc. raised its position in shares of Krystal Biotech by 40.7% during the third quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock valued at $278,416,000 after buying an additional 693,852 shares during the last quarter. Jennison Associates LLC raised its position in shares of Krystal Biotech by 485.0% during the third quarter. Jennison Associates LLC now owns 340,849 shares of the company’s stock valued at $39,538,000 after buying an additional 282,583 shares during the last quarter. Fred Alger Management LLC increased its position in Krystal Biotech by 4,608.6% in the third quarter. Fred Alger Management LLC now owns 167,485 shares of the company’s stock worth $19,428,000 after purchasing an additional 163,928 shares during the last quarter. TimesSquare Capital Management LLC bought a new stake in Krystal Biotech in the third quarter worth $14,272,000. Finally, Schonfeld Strategic Advisors LLC increased its position in Krystal Biotech by 356.8% in the third quarter. Schonfeld Strategic Advisors LLC now owns 83,635 shares of the company’s stock worth $9,702,000 after purchasing an additional 65,325 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Up 3.0 %

NASDAQ KRYS opened at $162.04 on Wednesday. The company has a fifty day moving average of $161.64 and a two-hundred day moving average of $130.95. The firm has a market capitalization of $4.62 billion, a price-to-earnings ratio of 2,025.75 and a beta of 0.85. Krystal Biotech, Inc. has a 52 week low of $82.09 and a 52 week high of $189.97.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of ($0.52) by $0.82. The firm had revenue of $42.14 million for the quarter, compared to analysts’ expectations of $27.43 million. During the same period in the previous year, the firm earned ($1.25) earnings per share. Equities research analysts anticipate that Krystal Biotech, Inc. will post 1.89 EPS for the current year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares in the company, valued at $265,138,786.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Krystal Biotech news, CAO Kathryn Romano sold 5,000 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total transaction of $829,400.00. Following the transaction, the chief accounting officer now directly owns 12,936 shares in the company, valued at approximately $2,145,823.68. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the transaction, the insider now owns 1,550,882 shares in the company, valued at $265,138,786.72. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,087 shares of company stock worth $6,210,591. Insiders own 14.10% of the company’s stock.

Analyst Ratings Changes

KRYS has been the topic of several research reports. Citigroup boosted their price target on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Stifel Nicolaus restated a “buy” rating and issued a $204.00 price target (up previously from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Guggenheim boosted their price target on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. HC Wainwright restated a “buy” rating and issued a $200.00 price target on shares of Krystal Biotech in a research report on Monday. Finally, William Blair restated an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, Krystal Biotech has an average rating of “Buy” and an average price target of $171.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).